Solid Start to the Year: LEO Pharma Delivers 13% Revenue Growth Driven by Strong Performance in Dermatology
In Q1 2024, LEO Pharma delivered a revenue growth of 13% in constant exchange rates (CER).
- In Q1 2024, LEO Pharma delivered a revenue growth of 13% in constant exchange rates (CER).
- Dermatology revenue grew 16% to DKK 2,444 million (Q1 2023: 2,150 million), driven by growth of Adtralza®/Adbry® for atopic dermatitis (AD) and solid growth in the core portfolio.
- “First quarter marks a solid start to 2024 with a 13% revenue growth and continued progress on our strategic priorities.
- I am pleased with the strong growth track record for our global dermatology portfolio, primarily driven by performance in North America.